Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Firsocostat (GS-0976) 是有效的乙酰辅酶A 羧化酶 (ACC) 抑制剂,抑制人类 ACC1 和 ACC2 的IC50分别为2.1和6.1 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 643 | 现货 | ||
2 mg | ¥ 945 | 现货 | ||
5 mg | ¥ 1,650 | 现货 | ||
10 mg | ¥ 2,660 | 现货 | ||
25 mg | ¥ 4,470 | 现货 | ||
50 mg | ¥ 6,380 | 现货 | ||
100 mg | ¥ 8,660 | 现货 | ||
500 mg | ¥ 17,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,980 | 现货 |
产品描述 | Firsocostat (GS-0976) is an inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits human ACC1 and ACC2 activity (IC50s of 2.1 and 6.1 nM, respectively) |
靶点活性 | ACC2:6.1 nM, ACC1:2.1 nM |
体外活性 | ND-630 inhibited hACC1 with an IC50 of 2.1 ± 0.2 nM and hACC2 with an IC50 of 6.1 ± 0.8 nM .?Inhibition was reversible and highly specific for ACC, as evidenced by the absence of an effect of ND-630 on the activity of 101 enzymes, receptors, growth factors, transporters, and ion channels of the Ricerca DrugMatrix Panel at 10 μM .?In addition, because the ACC dimerization site is not conserved among the mammalian carboxylases , ND-630 lacks the ability to inhibit any of these mechanistically related enzymes and therefore exhibits absolute specificity for ACC inhibition relative to other mammalian carboxylases. |
体内活性 | ND-630 reduces hepatic steatosis in a rat model of diet-induced obesity and in Zucker diabetic rats. It also improves insulin secretion stimulated by glucose and reduces hemoglobin A1c levels by 0.9% in Zucker diabetic rats. |
别名 | ND-630, NDI-010976, GS-0976 |
分子量 | 569.63 |
分子式 | C28H31N3O8S |
CAS No. | 1434635-54-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (87.78 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7555 mL | 8.7776 mL | 17.5553 mL | 43.8881 mL |
5 mM | 0.3511 mL | 1.7555 mL | 3.5111 mL | 8.7776 mL | |
10 mM | 0.1756 mL | 0.8778 mL | 1.7555 mL | 4.3888 mL | |
20 mM | 0.0878 mL | 0.4389 mL | 0.8778 mL | 2.1944 mL | |
50 mM | 0.0351 mL | 0.1756 mL | 0.3511 mL | 0.8778 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Firsocostat 1434635-54-7 Metabolism Acetyl-CoA Carboxylase NDI 010976 ND 630 GS0976 inhibit NDI010976 ND-630 NDI-010976 ACC, Acetyl Coenzyme A Carboxylase Inhibitor GS 0976 ND630 GS-0976 inhibitor